Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Bank of Hawaii Faces Revised Earnings Outlook Amid Mixed Results

Robert Sasse by Robert Sasse
September 19, 2025
in Analysis, Banking & Insurance, Earnings
0
Bank of Hawaii Stock
0
SHARES
113
VIEWS
Share on FacebookShare on Twitter

Market researchers at Zacks have downgraded their earnings projections for Bank of Hawaii. The firm now anticipates the bank will report a profit of $1.26 per share for Q2 2026, a downward revision of one cent from its prior forecast. The full-year 2026 estimate stands at $3.97 per share.

Strong Fundamentals Contrast with Revenue Miss

The institution’s latest quarterly report presented a complex picture. While earnings per share of $1.06 surpassed expectations by two cents, revenue of $174.48 million fell notably short of the $177.82 million analysts had projected.

Despite the revenue disappointment, several key performance indicators demonstrated robust growth:
* Net Income: $47.6 million (an 8.3% increase from the previous month)
* Net Interest Income: $129.7 million (a 3.1% rise compared to the prior quarter)
* Net Interest Margin: 2.39% (an increase of 7 basis points)
* Return on Equity: 12.50%

Dividend Stability Meets Growing Skepticism

Boasting a dividend yield of 4.26%, Bank of Hawaii ranks within the top quartile of dividend-paying stocks. Its payout ratio of 73.49% is considered sustainable and is expected to decline to 58.95% in the coming year.

Should investors sell immediately? Or is it worth buying Bank of Hawaii?

However, market sentiment shows signs of doubt. The short interest ratio climbed by 2.00% and now represents 9.18% of the freely tradable shares. Although the stock trades at a price-to-earnings multiple of 17.85, which remains below the industry average, this growing short position suggests increasing investor concern about its near-term price trajectory.

Interest Rate Sensitivity: A Double-Edged Sword

The bank’s significant exposure to interest rate fluctuations remains its primary challenge. With 57% of its investment portfolio in fixed-income assets, its performance is highly susceptible to changes in monetary policy.

Paradoxically, this sensitivity is currently a source of strength. As lower-yielding investments mature, the proceeds are being reinvested at today’s higher market rates. This dynamic is fueling the expansion in net interest income and margin. The average yield on loans increased by 8 basis points during the quarter to reach 4.80%.

The critical uncertainty for investors is whether this positive momentum can be sustained if the Federal Reserve decides to pivot its current interest rate policy.

Ad

Bank of Hawaii Stock: Buy or Sell?! New Bank of Hawaii Analysis from March 25 delivers the answer:

The latest Bank of Hawaii figures speak for themselves: Urgent action needed for Bank of Hawaii investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Bank of Hawaii: Buy or sell? Read more here...

Tags: Bank of Hawaii
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Ocugen Stock
Analysis

Ocugen Shares Slide Despite Positive Clinical Trial Results

March 25, 2026
ImmunityBio Stock
Analysis

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

March 25, 2026
IBM Stock
Analysis

IBM Shares Face Pressure from Analyst Downgrades and Acquisition Concerns

March 25, 2026
Next Post
Chinook Therapeutics Stock

A Tale of Two Legacies: Scientific Breakthrough and Legal Scandal at Chinook

PennyMac Services Stock

Mortgage Sector Surges as Fed Policy Shift Sparks Rally

SmartFinancial Stock

SmartFinancial Shares Reach Unprecedented Peak: Analyzing the Surge

Recommended

ServiceNow Stock

ServiceNow Accelerates AI Push with Pyramid Analytics Agreement

1 month ago
QuantumScape Stock

QuantumScape Leadership Exodus Sparks Investor Concerns

4 months ago
Fiserv Stock

Fiserv Shares Hit New Low Despite Strategic Acquisition Push

6 months ago
Star Copper Stock

Star Copper Secures Major Funding for Exploration Drive

2 weeks ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

IBM Shares Face Pressure from Analyst Downgrades and Acquisition Concerns

Battalion Oil Navigates Debt and Operational Overhaul

Divergent Analyst Views Highlight Coeur Mining’s Strategic Transition

Rocket Lab Stock Attracts Bullish Analyst Sentiment Amid Growth Trajectory

TSMC’s Arizona Expansion Gains Momentum Amid Record Retail Investor Interest

Salesforce Shares Face Pressure from External AI Innovation

Trending

Ocugen Stock
Analysis

Ocugen Shares Slide Despite Positive Clinical Trial Results

by SiterGedge
March 25, 2026
0

In a counterintuitive market reaction, Ocugen's stock price declined significantly following the announcement of encouraging 12-month data...

ImmunityBio Stock

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

March 25, 2026
Realty Income Stock

Realty Income’s Strategic Financing Defies High Interest Rate Environment

March 25, 2026
IBM Stock

IBM Shares Face Pressure from Analyst Downgrades and Acquisition Concerns

March 25, 2026
Battalion Oil Stock

Battalion Oil Navigates Debt and Operational Overhaul

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Ocugen Shares Slide Despite Positive Clinical Trial Results
  • Regulatory Rebuke Sends ImmunityBio Shares Tumbling
  • Realty Income’s Strategic Financing Defies High Interest Rate Environment

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com